There’s Still Time: Paving a Path for Value-Based Dementia Care in Canada

Alzheimer’s disease is a growing concern in Canada. Scientific progress is shedding more light on its pathology and opening doors to new treatments. Are Canada’s healthcare systems able to support access?

Document Highlights

Dementia currently affects over half a million Canadians. By 2030, this will nearly double to 912,000. Alzheimer’s disease (AD), the most common cause of dementia, is the eighth leading cause of death in Canada, killing over 6,000 Canadians every year. In 2021, AD and other dementias will cost Canada an estimated $11.3 billion in both direct and indirect expenses. This is projected to rise to $16.6 billion by 2030.

There’s Still Time: Paving a Path for Value-Based Dementia Care in Canada shines light on the significant gaps that exist in Canada’s dementia care capacity. Disease-modifying therapies for AD in Canada are on the horizon. They have the potential to bring lasting change by either slowing down or stopping its progression. They offer hope—shifting the perspective that AD is an incurable and fatal disease. To benefit from them, however, a systemic change of our healthcare system is urgently needed.